


JC03 Rec'd PCT/PTO 1 3 OCT 2005

PCT #6



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on October 10, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti Appling

Attorney Docket No. 407T-301110US
Client Ref. No. 2002-340-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan M. Fogelman, et al.

Application No.: 10/520,207

International Filing Date: April 1, 2003

For: G-TYPE PEPTIDES TO
AMELIORATE
ATHEROSCLEROSIS

Examiner: Jeffrey E. Russel

Art Unit: 1654

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 10/120,508 (now U.S. Patent 6,930,085) filed August 5, 2002. *An additional 1449 form citing an additional reference is also enclosed. A copy of the newly cited reference is enclosed.*


Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 10/120,508 (now U.S. Patent 6,930,085) filed August 5, 2002 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Tom Hunter", with a stylized flourish at the end.

Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/520,207
Filing Date	April 1, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301110US
Date Submitted	October 10, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,358,934		Borovsky et al	10-1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	2	WO	91/05043 A1		Schering	04-1991		
	3	WO	00/34469 A1		Research Foundation	06-2000		
	4	WO	02/22161 A2		Universitair Medisch	03-2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

Application Number	10/680,083
Filing Date	October 6, 2003
First Named Inventor	Dallas A. Rabenstein
Group Art Unit	1653
Examiner Name	Davenport, A.
Attorney Docket Number	407T-891101US
Date Submitted	February 27, 2004

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	EP	1186299 A1			13.02.2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	2	PCT Search Report	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,733,879		Rosseneu et al.	3/31/1998	
	2	6,004,925		Dasseux et al.	12/21/1999	
	3	6,037,323		Dasseux et al.	3/14/2000	
	4	6,046,166		Dasseux et al.	4/4/2000	
	5	2001/0005714 A1		Boffelli et al.	6/28/2001	
	6	6,265,377		Dasseux et al.	7/24/2001	
	7	6,287,590		Dasseux et al.	9/11/2001	
	8	6,329,341		Dasseux et al.	12/11/2001	
	9	6,376,464		Dasseux et al.	4/23/2002	
	10	6,455,088		Dasseux et al.	9/24/2002	
	11	6,518,412		Dasseux et al.	2/11/2003	
	12	6,573,239		Dasseux et al.	6/3/2003	
	13	6,602,854		Dasseux et al.	8/5/2003	
	14	2003/0045460 A1		Fogelman et al.	3/6/2003	
	15	6,630,450		Dasseux et al.	10/7/2003	
	16	6,716,816		Dasseux et al.	4/6/2004	
	17	6,734,169		Dasseux et al.	5/11/2004	
	18	6,753,313		Dasseux et al.	6/22/2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	19	IN	185761		Council of Scientific and	04/28/2004		

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 23, 2004

				Industrial Research			
	20	WO	97/36927	Boffelli et al.			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	21	Aravinda, S., Shamala, N., Das, C. , Sriranjini, A. , Karle, I. And Balaram, P. Aromatic-Aromatic Interactions in Crystal Structures of Helical Peptide Scaffolds Containing Projecting Phenylalanine Residues, J.Am Chem Soc. 2003; 125:5308-5315.	
	22	Ashby D, Gamble J, Vadas M, Fidge N, Siggins S, Rye K, Barter PJ. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. <i>Atherosclerosis</i> . 2001;154:113-121.	
	23	Ashby DT, Rye K-A, Clay MA., Vadas MA, Gamble J, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 1998,18:1450-1455.	
	24	Baker PW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical cell endothelial cells. <i>Journal of Lipid Research</i> , 1999, 40:345-353.	
	25	Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. <i>J Lipid Res</i> 2000;41:1261-1267.	
	26	Barter PJ, Baker PW, Rye K-A.. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. <i>Current Opinion in Lipidology</i> , 2002, 13:285-288.	
	27	Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. <i>Atherosclerosis</i> , 1996, 121:1-12.	
	28	Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



		Circulating cell adhesion molecules and death in patients with coronary artery disease. <i>Circulation</i> 2001;104:1336-1342.	
	29	Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. <i>Arterioscler Thromb Vasc Biol</i> 2000;20:2630-2635.	
	30	Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. <i>Proc Natl Acad Sci U S A.</i> 1992;89:10316-10320.	
	31	Burger D, Dayer J-M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? <i>Autoimmunity Reviews</i> 2002;1:111-117.	
	32	Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. <i>Biochem Biophys Res Commun.</i> 1997;238:61-65.	
	33	Calabresi L, Gomasaschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated cellular adhesion molecules in subjects with low HDL-cholesterol. <i>Arterioscler Thromb Vasc Biol</i> 2002;22:656-661.	
	34	Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. <i>Blood</i> 1990;76:965-970.	
	35	Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species oxidation of LDL by myeloperoxidase and reactive nitrogen species. <i>Arterioscler Thromb Vasc Biol.</i> 2000;20:1716-1723.	
	36	Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. <i>JAMA</i> 1986;256:2835-2838.	
	37	Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. <i>Circ Res.</i> 2002;90:974-980.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(Use as many sheets as necessary)

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004




38	Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. <i>Biochem J.</i> 1996;314:739-742.		
39	Clay MA, Pyle DH, Rye K-A, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. <i>Atherosclerosis</i> , 2001,157:23-29..		
40	Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. <i>rculation</i> 2001;103:108-112.		
41	Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. <i>Arterioscler Thromb Vasc Biol.</i> 1995;15:1987-1994.		
42	Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. <i>Arterioscler Thromb Vasc Biol.</i> 1999;19:910-917.		
43	Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. <i>Journal of Clinical Investigation</i> 2001;107:1255-1262.		
44	Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. <i>Circulation.</i> 2001;103:2277-2282.		
45	Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:1662-1667.		
46	Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS, Breslow JL. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. <i>J Clin Invest.</i> 1999;104:31-39 .		
47	Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. <i>Am J Pathol</i> 2003;163:1117-1125.		
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

48	Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and Eselectin in human atherosclerosis. <i>J Pathol</i> 1993;171:223-229.
49	De Caterina R, Bernini W, Carluccio MA, Liao JK, Libby P. Structural requirements for inhibition of cytokine-induced endothelial activation by unsaturated fatty acids. <i>J. Lipid Res.</i> 1998;39:1062-1070.
50	Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, Shah PK, Nilsson J, Cercek B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. <i>Biochem Biophys Res Commun.</i> 1999;264:465-468.
51	Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. <i>Arterioscler. Thromb.</i> 1994;14:1775-1783.
52	Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. <i>J. Biol. Chem.</i> 1982;257:6653-6655.
53	Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. <i>Proc Natl Acad Sci U S A.</i> 1980;77:2214-2218.
54	Fogelman AM. When good cholesterol goes bad. <i>Nat Med</i> 2004;10:902-903.
55	Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. <i>J. Lipid Res.</i> 2002;43:477-485.
56	Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. <i>N. Engl. J. Med.</i> 1999; 340: 448-454.
57	Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. <i>J Biol Chem</i> 1998;273:6088-6095.
58	Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004



		of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. <i>J Biol Chem</i> 1998;273:6080-6087.	
	59	Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. <i>J Clin Invest</i> 2002;109:1311-1319.	
	60	George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. <i>Circulation</i> . 2001;104:1646- 1650.	
	61	Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. <i>Am. J. Med.</i> 1977;62: 707-714.	
	62	Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. <i>Arterioscler Thromb Vasc Biol</i> . 2000;20:2100-2105.	
	63	Henricksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low density lipoproteins. <i>Proc Natl Acad Sci U S A</i> . 1981;78:6499-6503.	
	64	Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. <i>Atherosclerosis</i> 1979; 32:213-229.	
	65	Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. <i>Circulation</i> 1997;96:4219- 4225.	
	66	Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. <i>J Clin Invest</i> 2003;111:357-362.	
	67	Karle, I., Gopi, H., and Balaram, P. Crystal structure of hydrophobic 19-residue peptide helix containing three centrally located D amino acids PNAS 2003;100:24:13946-13951	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

- | | |
|----|--|
| 68 | Karle, I, Prasad, S. and Balaram, P. A combined extended and helical backbone for Boc-(Ala-Leu-Ac7C)2-OME, <i>Peptides Res.</i> 2004; 63:174-180 |
| 69 | Ko Y, Haring R, Stiebler H, Wiczorek AJ, Vetter H, Sachinidis A. Highdensity lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. <i>Atherosclerosis</i> 1993;99: 253-259. |
| 70 | Kume N, Cybulsky MI, Gimbrone Jr MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. <i>Journal of Clinical Investigation</i> 1992;90:1138-1144. |
| 71 | Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. <i>Cell</i> 1991;65:859-873. |
| 72 | Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. <i>Science</i> 2001;292:2083-2086. |
| 73 | Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. <i>Proc. Natl. Acad. Sci. USA</i> 1993;90 : 12040-12044. |
| 74 | Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. <i>Arteriosclerosis and Thrombosis</i> 1993;13:197-204. |
| 75 | Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. <i>Circulation</i> 2002;105:1135-1143. |
| 76 | Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. <i>Circ Res.</i> 2002;91:120- 126. |
| 77 | Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. <i>Circ. Res.</i> 1994;74 : 1149-1156. |
| 78 | Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apoA-I/phosphosphatidylcholine discs on plasma lipoproteins in humans.. <i>Arterioscler Thromb Vasc Biol.</i> 1999;19:979-989. |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(use as many sheets as necessary)

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

79	Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-b-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. <i>J Lipid Res</i> 2001;42:1586-1593.
80	Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. <i>J. Lipid Res.</i> 2004; 45: 993-1007.
81	Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre- □ high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apoE-null mice. <i>Circulation</i> 2004;109:r120-r125.
82	Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:481-488.
83	Navab M, Hama S, Hough G et al. Oral synthetic phospholipids (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. <i>Circulation</i> 2003;108:1735-1739.
84	Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. <i>J Lipid Res</i> 2001;42:1308-1317.
85	Navab M, Hama-Levy, S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. <i>J. Clin. Invest.</i> 1997; 99: 2005-2019.
86	Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. <i>Journal of Clinical Investigation</i> 1991;88:2039-2046.
87	Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima two hours after bolus infusion of low density lipoprotein: A deep-etch and immuno-localization study of ultra-rapidly frozen tissue. <i>Arteriosclerosis and Thrombosis</i> 1991;11:1795-1805.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PAPER

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

88	Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson SR, Harker LA. Anti- VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. <i>J Vasc Surg</i> 1997;26:87-93.
89	Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. <i>Nature</i> 1998;394:200- 203.
90	O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. <i>Circulation</i> 1996;93:672-82.
91	O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. <i>Circulation</i> 2001;104:1978-1983.
92	Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, Nilsson J, Cercek B. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. <i>Arterioscler Thromb Vasc Biol</i> 2000;20:1729-1736.
93	Papo N, Oren Z, Pag U, et al. The consequence of sequence alteration of an amphipathic α -helical antimicrobial peptide and its diastereomers. <i>J. Biol. Chem.</i> 2002;277(37): 33913-33921.
94	Parthasarathy S, Santanam N. Mechanisms of oxidation antioxidants, and atherosclerosis. <i>Curr Opin Lipidol</i> 1994;5:371-375.
95	Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. <i>Circulation.</i> 2001;103:2531-2534.
96	Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. <i>Circulation.</i> 2000;102:2165-2168.
97	Ou J, Geiger T, Zhijun O, et al. AP-4F, antennapedia peptide linked to an amphipathic α helical peptide, increases the efficiency of lipofectamine-mediated gene transfection in endothelial cells. <i>Biochem Biophys Res Commun</i> 2003;305:605-610.
98	Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemic and sickle cell disease. <i>Circulation</i> 2003;107:2337-2341.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

99	Ou Z, Ou J, Ackerman AW et al. L-4F, an apolipoprotein A-I mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. <i>Circulation</i> 2003;107:1520-1524.
100	Ranganathan, D, Kurur, S, Kunwar, A, Sarma, A, Vairamani, M, Karle, I. Channel-forming, self-assembling, bishelical amphiphilic peptides: design, synthesis and crystal structure of Py(Aibn) ₂₁ n=2, 3, 4. <i>J. Peptide Res.</i> 2000 56:416-426
101	Reape TJ, Groot PH. Chemokines and atherosclerosis. <i>Atherosclerosis</i> 1999;147:213-225.
102	Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:542- 547.
103	Reddy ST, Nguyen JT, Grijalva V, et al. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. <i>Arterioscler Thromb Vasc Biol</i> 2004;24:1676-1681.
104	Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. <i>Circulation</i> 2002;105:2-4.
105	Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. <i>Circulation</i> 2001;104:2447-2452.
106	Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of highdensity lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. <i>Biochem J.</i> 1993;294:771-778.
107	Shah PK, Nilsson J, Kaul S. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , 1998;97(8): 780-785.
108	Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoproteins A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein Edeficient mice:

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)


Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004



		potential implications for acute plaque stabilization. <i>Circulation</i> . 2001;103:3047-3050.	
	109	Shih D.M., Xia Y-R., Wang X-P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. <i>J. Biol. Chem.</i> , 2000;275:17527-17535.	
	110	Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta integrin. <i>J Clin Invest</i> 1999;103:613-625.	
	111	Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. <i>JAMA</i> 2003;289:1675-1680.	
	112	Singh IP, Baron S. Innate defences against viremia. <i>Rev Med Virol</i> 2000;10:395-403.	
	113	Sorescu D, Szocs K, Griendling KK. NAD(P)H oxidases and their relevance to atherosclerosis. <i>Trends Cardiovas Med</i> 2001;11:124-131.	
	114	Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. <i>Circulation</i> . 2002;105:1399- 1402.	
	115	Springer TA. Adhesion receptors of the immune system. <i>Nature</i> 1990;346:425-434.	
	116	Stannard AK, Khan S, Graham A, Owen JS, Allen SP. Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. <i>Atherosclerosis</i> 2001;154:31-38.	
	117	Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. <i>J. Lipid Mediators Cell Signal</i> . 1996;13:73-88.	
	118	Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. <i>Circulation</i> 2002;106:484-490.	
	119	Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

		Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. <i>J Clin Invest</i> 1995;96:2758- 2767.	
	120	Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. <i>Circulation</i> 2001;103:2283-2288.	
	121	Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. <i>Circulation</i> 2002; 106:1127-1132.	
	122	Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. <i>Circulation</i> . 2002;106:1439-1441.	
	123	Walpolo PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. <i>Arterioscler Thromb Vasc Biol</i> 1995;15:2-10.	
	124	Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density lipoprotein. <i>J Clin Invest</i> 1995;95:774-782.	
	125	Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. <i>J Clin Invest</i> 1995;96:2882-2891.	
	126	Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. <i>J Biol Chem</i> . 1999;274:33143-33147.	
	127	Yamashita S, Maruyama T, Hirano K, et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. <i>Atherosclerosis</i> 2000;152:271-285.	
	128	Yan D, Navab M, Bruce C et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. <i>J Lipid Res</i> 2004;45:1852-1858.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY TO BE MADE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left;">Complete if Known</th> </tr> <tr> <td style="width: 60%;">Application Number</td> <td>10/120,508</td> </tr> <tr> <td>Filing Date</td> <td>April 5, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Alan M. Fogelman</td> </tr> <tr> <td>Group Art Unit</td> <td>1654</td> </tr> <tr> <td>Examiner Name</td> <td>Jeffrey E. Russel</td> </tr> <tr> <td>Attorney Docket Number</td> <td>407T-301100US</td> </tr> <tr> <td>Date Submitted</td> <td>November 23, 2004</td> </tr> </table>	Complete if Known		Application Number	10/120,508	Filing Date	April 5, 2002	First Named Inventor	Alan M. Fogelman	Group Art Unit	1654	Examiner Name	Jeffrey E. Russel	Attorney Docket Number	407T-301100US	Date Submitted	November 23, 2004
Complete if Known																	
Application Number	10/120,508																
Filing Date	April 5, 2002																
First Named Inventor	Alan M. Fogelman																
Group Art Unit	1654																
Examiner Name	Jeffrey E. Russel																
Attorney Docket Number	407T-301100US																
Date Submitted	November 23, 2004																

129		Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. <i>J. Clin. Invest.</i> 1988;82: 803-807.	
130		Zeihner AM, Schachinger V. Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. <i>Circulation</i> 1994;89:2525-2532.	
131		Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. <i>J Biol Chem</i> 2002;277:46116-46122.	
132		Zhang WJ, Stocker R, McCall MR, Forte TM, Frei B. Lack of inhibitory effect of HDL on TNFalpha-induced adhesion molecule expression in human aortic endothelial cells. <i>Atherosclerosis</i> 2002;165:241-249.	
133		Zhao L, Cuff CA, Moss e, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. <i>J Biol Chem</i> 2002;277:35350-35356.	
134		Anantharamaiah <i>et al.</i> (1993) Pp. 109 In: The Amphipathic Helix, (Ed R.M. Epand. CRC press, Ann Arbor Mi)	
135		Bailey <i>et al.</i> (2001) <i>Biochemistry</i> ; 40: 11828-11840	
136		Clerio <i>et al.</i> (1999) <i>Biochem J</i> ; 344: 375-383	
137		Dota <i>et al.</i> (1999) <i>Exp Eye Res</i> ; 69: 705-708	
138		Fleming <i>et al.</i> (1999) <i>J Molecular Endocrinology</i> ; 23:199-208	
139		Gelissen <i>et al.</i> (1998) <i>Biochem J</i> ; 331: 231-237	
140		Griswold (1987) <i>Biochemistry</i> ; 26:3297-3303	
141		Hammad <i>et al.</i> (1997) <i>J Biol Chem</i> ; 272: 18644-18649	
142		Han <i>et al.</i> (2001) <i>Nature Medicine</i> ; 7 338-343	
143		Hasan <i>et al.</i> (2000) <i>Hum Pathol</i> ; 31: 691-697	
144		Hochgrebe <i>et al.</i> (1999) <i>Experimental Cell Research</i> ; 249: 13-21	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY TO PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO <div style="border: 2px solid black; border-radius: 50%; padding: 10px; width: 150px; float: left; margin-right: 10px;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT OCT 13 2005 PATENT & TRADEMARK OFFICE </div> <div style="clear: both;"></div> (use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/120,508</td> </tr> <tr> <td>Filing Date</td> <td>April 5, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Alan M. Fogelman</td> </tr> <tr> <td>Group Art Unit</td> <td>1654</td> </tr> <tr> <td>Examiner Name</td> <td>Jeffrey E. Russel</td> </tr> <tr> <td>Attorney Docket Number</td> <td>407T-301100US</td> </tr> <tr> <td>Date Submitted</td> <td>November 23, 2004</td> </tr> </table>	Complete if Known		Application Number	10/120,508	Filing Date	April 5, 2002	First Named Inventor	Alan M. Fogelman	Group Art Unit	1654	Examiner Name	Jeffrey E. Russel	Attorney Docket Number	407T-301100US	Date Submitted	November 23, 2004
Complete if Known																	
Application Number	10/120,508																
Filing Date	April 5, 2002																
First Named Inventor	Alan M. Fogelman																
Group Art Unit	1654																
Examiner Name	Jeffrey E. Russel																
Attorney Docket Number	407T-301100US																
Date Submitted	November 23, 2004																

145	Hough <i>et al.</i> (200`) Cancer Res; 61: 3869-3876	
146	Ishikawa <i>et al.</i> (1998) Arterioscler Thromb Vasc Biol; 18: 665-672	
147	Ishikawa <i>et al.</i> (2001) Atherosclerosis; 158: 215-225	
148	Jenne <i>et al.</i> (1989) <i>Proc Natl Acad Sci USA.</i> ; 86: 7123-7127	
149	Khan <i>et al.</i> (2000) Pathology; 258-261	
150	Kissinger <i>et al.</i> (1982) Biol Reprod 1982; 27:233-240	
151	Landes (1995) Pp. 1-12 In: Clusterin: Role in Vertebrate Development, Function, and Adaptation (Harmony JAK Ed.) pp 1-12, R.G.	
152	Macknes <i>et al.</i> (1997) Arterioscler Thromb Vasc Biol; 17: 1233-1238	
153	McLaughlin <i>et al.</i> (2000) J Clin Invest; 106:1105-1113	
154	Mitsuhashi <i>et al.</i> (1997) J Clin Invest; 100: 847-854	
155	Morrissey <i>et al.</i> (2001) J Biochem Biophys Methods; 48: 13-21	
156	Navab <i>et al.</i> (1997) J Clin Invest; 99:2005-2019	
157	Navab <i>et al.</i> (2000) J Lipid Res; 41:1495-1508	
158	Navab <i>et al.</i> (2000) J Lipid Research; 41:1481-1494	
159	Navab <i>et al.</i> (2001) Arterioscler Thromb Vasc Biol. 2001; 21:481-488	
160	Navab <i>et al.</i> (2001) Arterioscler Thromb Vasc Biol; 21:1451-1457	
161	Navab <i>et al.</i> (2002) Circulation; 105:290-292	
162	Newkirk <i>et al.</i> (1999) J Rheumatol; 26: 597-603	
163	Nishida <i>et al.</i> (1999) <i>Br J Ophthalmol</i> ; 83: 1178-1182)	
164	Redondo <i>et al.</i> (2000) Am J Pathol; 157:393-399	
165	Segrest <i>et al.</i> (1990). Proteins:Structure, Function and Genetics; 8:103-117 Erratum (1991) Proteins:Structure, Function and Genetics 1991; 9:79	
166	Silkensen <i>et al.</i> (1999) Pept Res; 54: 449-457	
167	Steinberget <i>et al.</i> (1997) Clin Cancer Res; 3: 1707-1711	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY TO PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/120,508
Filing Date	April 5, 2002
First Named Inventor	Alan M. Fogelman
Group Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-301100US
Date Submitted	November 23, 2004

168	Van Lenten <i>et al.</i> (2001) Circulation;103: 2283-2288	
169	Van Lenten <i>et al.</i> (2001) J Biol Chem;276: 1923-1929	
170	Wehrli <i>et al.</i> (2001) Nature Medicine; 7: 977-978	
171	Wellman <i>et al.</i> (2000) Blood; 96: 398-404	
172	Wong <i>et al.</i> (2000) Vision; 6: 184-191	
173	Xu <i>et al.</i> (2000) J Biol Chem; 275: 31770-3177	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	01	3,767,040		Tushaus	10-23-1973	
	02	4,155,913		Hellerbach et al.	05-22-1979	
	03	4,643,988		Segrest et al.	02-17-1987	
	04	5,721,138		Lawn	02-24-1998	
	05	5,733,549		Yamada et al.	03-31-1998	
	06	5,814,467		Curtiss et al.	09-29-1998	
	07	5,854,238		Kempen	12-29-1998	
	08	6,037,323		Dasseux et al.	03-14-2000	
	09	6,086,918		Stern et al.	07-11-2000	

Examiner Initials		Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	10	WO	97/36927	A1	Boffelli et al.	10-09-1997		
	11	WO	99/47566	A1	The UAB Research Foundation	09-23-1999		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examin er Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	12	ANANTHARAMAIAH (1986) "Synthetic Peptide Analogs of Apolipoproteins." <i>Methods in Enzymology</i> 128:627-647	
	13	ANANTHARAMAIAH and GARBER (1996) "Chromatographic Methods for Quantitation of Apolipoprotein A-I." <i>Meth. Enzymol.</i> 263: 267-282	
	14	ANANTHARAMAIAH et al. (1985) "Studies of Synthetic Peptide of the Amphipathic Helix." <i>The Journal of Biological Chemistry</i> 260:10248-10255	
	15	ANANTHARAMAIAH et al. (1990) "Use of Synthetic Peptide Analogues to Localize Lecithin: Cholesterol Acyltransferase Activating Domain in Apolipoprotein A-I." <i>Arteriosclerosis</i> 10:95-105	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003




16	ANANTHARAMAIAH et al. (1993) "An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins." Chapter. 6:109-142 In: <i>The Amphipathic Helix</i> (Epanand, R. M., ed), CRC Press, Boca Raton, FL	
17	ARMSTRONG et al. (1993) D amino acid levels in human physiological fluids, <i>Chirality</i> , 5: 375-378	
18	ATLAS-WHITE et al. (2000) "Localisation of clusterin in normal human sperm by immunogold electron microscopy." <i>Pathology</i> ; 258-261	
19	BADIMON et al. (1990) "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit." <i>J. Clinical Investigation</i> 85:1234-1241	
20	BAILEY et al. (2001) "Clusterin, a binding protein with a molten globule-like region." <i>Biochemistry</i> ; 40: 11828-11840	
21	BAUER et al. (1982) "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action" <i>Life Sciences</i> 31:1133-1140.	
22	BOFFELLI et al. (1997) "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" <i>Biochemistry</i> 36:10784-10792.	
23	BOFFELLI et al. (1997) "The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins." <i>FEBS Letters</i> , 411: 7-11	
24	BORHANI et al. (1999) "Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation." <i>Proc. Natl. Acad. Sci. USA</i> . 94:12291-12296	
25	BROUILLETTE and ANANTHARAMAIAH (1995) "Structural models of human apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1256: 103-129	
26	BROUILLETTE et al. (2001) "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" <i>Biochemica et Biophysica Acta</i> 1531:4-46.	
27	CALERO et al. (1999) "Functional and structural properties of lipid-associated apolipoprotein J (clusterin)." <i>Biochem J</i> ; 344: 375-383	
28	Canadian Pharmacists Association, Starlix General Monograph. http://cpha.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm	
29	CHUNG et al. (1985) "Studies of Synthetic Peptide Analogs of the Amphipathic Helix." <i>J. Biol. Chem.</i> 60(18): 10256-10262	
30	DATTA et al. (2001) "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide." <i>J Lipid Research</i> 42:1096-1104.	
31	DAVIDSON et al. (1994) "The Influence of Apolipoprotein Structure on the Efflux of Cellular Free Cholesterol to High Density Lipoprotein." <i>J. Biol. Chem.</i> 269(37): 22975-22982	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003




32	DIEDERICH et al. (2001) "Apolipoprotein AI and HDL ₃ Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42." <i>Atherosclerosis</i> 159:313-324.
33	DOOLEY et al. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022.
34	DOTA et al. (1999) "Clusterin in human corneal endothelium and aqueous humor." <i>Exp Eye Res</i> ; 69: 705-708
35	DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30
36	EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960
37	EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396
38	FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9
39	FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228
40	FIELDING et al. (1972) "A Protein of Lecithin: Cholesterol Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498
41	FLEMING et al. (1999) "Clusterin is expressed in the anterior and intermediate lobes, but not in the posterior pituitary of sheep." <i>J Molecular Endocrinology</i> ; 23:199-208
42	FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832
43	FUESSL et al. (1987) "Oral Absorption of the Somatostatin Analogue SMS 201-995: Theoretical and Practical Implications" <i>Clinical Science</i> 72: 255-257.
44	GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894
45	GARBER et al. (1997) <i>Circulation</i> 96(8):I-490, Abstract 2744.
46	GARBER et al. (1999) <i>Circulation</i> 100(18):I-538, Abstract 2838.
47	GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:545-552

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003



48	GELISSEN <i>et al.</i> (1998) "Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?" <i>Biochem J</i> ; 331: 231-237	
49	GLOMSET (1968) "The Plasma lecithin: cholesterol acyltransferase reaction." <i>J. Lipid Res.</i> 9:155-167	
50	GONG <i>et al.</i> (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342	
51	GRISWOLD (1987) "Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells." <i>Biochemistry</i> ; 26:3297-3303	
52	GURFINKEL <i>et al.</i> (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.	
53	HAMASE <i>et al.</i> (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.	
54	HAMMAD <i>et al.</i> (1997) "Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide." <i>J Biol Chem</i> ; 272: 18644-18649	
55	HAN <i>et al.</i> (2001) "Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia." <i>Nature Medicine</i> ; 7 338-343	
56	HARDY <i>et al.</i> (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299.	
57	HASAN <i>et al.</i> (2000) "Clusterin/apoJ expression during the development of hemangioma." <i>Hum Pathol</i> ; 31: 691-697	
58	HASHIMOTO <i>et al.</i> (2000) "Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles." <i>J. Pharmaceutics & Therapeutics</i> 50(2):197-204	
59	HAUSER <i>et al.</i> (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850.	
60	HAYRY <i>et al.</i> "Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat." <i>FASEB J.</i> 9(13):1336-1344	
61	HOCHGREBE <i>et al.</i> (1999) "A reexamination of the role of clusterin as a complement regulator." <i>Experimental Cell Research</i> ; 249: 13-21	
62	HOUGH <i>et al.</i> (2001) "Coordinately up-regulated genes in ovarian cancer." <i>Cancer Res</i> ; 61: 3869-3876	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003

63	HYKA et al. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1beta and Tumor Necrosis Factor-alpha by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes." <i>Blood</i> 97:2381-2389.
64	ISHIKAWA et al. (1998) "Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta." <i>Arterioscler Thromb Vasc Biol</i> : 18: 665-672
65	ISHIKAWA et al. (2001) "Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study." <i>Atherosclerosis</i> ; 158: 215-225
66	JENNE et al. (1989) "Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid." <i>Proc Natl Acad Sci USA</i> ; 86: 7123-7127
67	JOHNSON et al. (1991) "Cholesterol transport between cells and high-density lipoproteins." <i>Biochim. Biophys. Acta</i> . 1085: 273-298
68	JONAS (1991) "Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1084: 205-220
69	JONAS (2000) Lecithin cholesterol acyltransferase." <i>Biochim. Biophys. Acta</i> 1529: 245-256
70	JONES et al. (1992) "Computer Programs to Identify and Classify Amphipathic alpha Helical Domains" <i>Journal of Lipid Research</i> 33:287-296.
71	KIGASAWA et al. (1995) "Inhibition of corneal ulceration by tetrapeptidyl hydroxamic acid." <i>Jap. J. Ophthalmology</i> 39(1):35-42
72	KISSINGER et al. (1982) "Analysis of Sertoli cell-secreted proteins by two-dimensional gel electrophoresis." <i>Biol Reprod</i> 1982; 27:233-240
73	KREIGER (1999) "Charting The Fate of the "Good Cholesterol": Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi." <i>Ann Rev. Biochem.</i> 68: 523-558
74	KULLMAN et al. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673.
75	LANDES (1995) Pp. 1-12 In: Clusterin: Role in Vertebrate Development, Function, and Adaptation (Harmony JAK Ed.) pp 1-12, R.G.
76	LEVI et al. (2000) "A retro-inverso miniantibody with anti-HIV activity." <i>Aids Res. & Human Retrovirus</i> 16(1):59-65.
77	LUNDIN et al. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
	Application Number		10/120,508	
	Filing Date		April 5, 2002	
	First Named Inventor		Alan M. Fogelman	
	Group Art Unit		1654	
	Examiner Name		Jeffrey E. Russel	
	Attorney Docket Number		407T-301100US	
	Date Submitted		November 26, 2003	

78	MACKNESS <i>et al.</i> (1997) "Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis." <i>Arterioscler Thromb Vasc Biol</i> ; 17: 1233-1238
79	MACKNESS <i>et al.</i> (2001) "Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?" <i>Arterioscler Thromb Vasc Biol</i> ; 21:1451-1457
80	MAN <i>et al.</i> (1987) "D-aspartate in human brain." <i>J Neurochem</i> 48:510-515
81	MCLAUGHLIN <i>et al.</i> (2000) "Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis." <i>J Clin Invest</i> ; 106:1105-1113
82	MERRIFIELD <i>et al.</i> (1995) "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453.
83	MISHRA <i>et al.</i> (1994) "Interactions of Synthetic Peptide Analogs of the Class A" <i>J. Biol. Chem.</i> 269: 7185-7191
84	MISHRA <i>et al.</i> (1995) "Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic alpha-Helices on Lipid Interaction." <i>J. Biol. Chem.</i> 270: 1602-1611
85	MISHRA <i>et al.</i> (1998) "Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic alpha-Helices" <i>Biochemistry</i> 37: 10313-10324
86	MITSUHASHI <i>et al.</i> (1997) "Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix." <i>J Clin Invest</i> ; 100: 847-854
87	MOR <i>et al.</i> (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides, <i>TIBS</i> , 17: 481-485
88	MORRISSEY <i>et al.</i> (2001) "An antigen capture assay for the measurement of serum clusterin concentrations." <i>J Biochem Biophys Methods</i> ;48: 13-21
89	NAGATA <i>et al.</i> (1994) "Distribution of free D-serine in vertebrate brains", <i>Brain Res.</i> , 634: 291-295.
90	NAGATA <i>et al.</i> (1995) "Free D-serine concentration in normal and Alzheimer human brain", <i>Brain Res. Bull.</i> , 38(2): 181-183
91	NAVAB <i>et al.</i> (1997) "Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio." <i>J Clin Invest</i> ; 99:2005-2019
92	NAVAB <i>et al.</i> (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1." <i>J. Lipid Res.</i> 41: 1481-1494
93	NAVAB <i>et al.</i> (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3." <i>J. Lipid Res.</i> 41: 1495-1508
94	NAVAB <i>et al.</i> (2001) "HDL and the inflammatory response induced by LDL-derived oxidized phospholipids." <i>Arterioscler Thromb Vasc Biol.</i> 21:481-488

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003




95	NAVAB et al. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292.
96	NEWKIRK et al. (1999) "Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an anti-inflammatory protein." <i>J Rheumatol</i> ; 26: 597-603
97	NISHIDA et al. (1999) "Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies." <i>Br J Ophthalmol</i> ; 83: 1178-1182.
98	NOMOTO et al. (1998) "Improved of intestinal absorption of peptide drugs by Glycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter." <i>J. Pharmaceutics Science</i> 87(3):326-332.
99	OHTANI et al. (1995) Age-related changes in D-aspartic acid of rat teeth, <i>Growth Develop. & Aging</i> , 59: 55-61
100	ORAM and YOKOYAMA (1996) "Apolipoprotein-mediated removal of cellular cholesterol and phospholipids." <i>J. Lipid Res.</i> 37: 2473-2491
101	OWENS et al. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150.
102	PAIGEN et al. (1990) "Atherosclerosis Susceptibility Differences among Progenitors of Recombinant Inbred Strains of Mice." <i>Arteriosclerosis</i> 10: 316-323
103	PALGUNACHARI et al. (1996) "Only the Two End Xelises of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity." <i>Arteriosclerosis, Thrombosis, & Vascular Biology</i> 16: 328-338
104	PANIZZUTTI et al. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299.
105	PAPPENHEIMER et al. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945.
106	PAPPENHEIMER et al. (1997) "Absorption and Excretion of Undegradable Peptides: Roles of Lipid Solubility and Net Charge." <i>J. Pharmacology & Experimental Therapeutics</i> 280(1):292-300
107	PATSZTY et al. (1994) "Apolipoprotein AI Transgene Corrects Apolipoprotein E Deficiency-induced Atherosclerosis in Mice." <i>J. Clinical Investigation</i> 94:899-903
108	PENG et al. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochem. Int'l</i> 38:437-443.
109	PHARMALICENSING (27 Jan. 2001) Esperion Builds a Novel Peptides Program (2 pages)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003




110	PHARMALICENSING (28 Jan. 2001) Multiple Peptide Systems Forms Joint Venture With Elan	
111	PHARMALICENSING (28 Jan. 2001) Unigene to Receive Patent for Delivery of Peptide Pharmaceuticals (2 pages)	
112	PHILLIPS et al. (1993) "Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events." <i>Circulation</i> 88: 2762-2770	
113	PILONE (2000) D-amino acid oxidase: new findings. <i>CMLS, Cell. Mol. Life Sci.</i> , 57: 1732-1747	
114	PLUMP et al. (1994) "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses stherosclerosis in the apolipoprotein E-deficient mouse." <i>Proc. Natl. Acad. Sci. USA</i> 91:9607-9611	
115	PURDUE NEWS (October 2000) 'Microspheres' Offer Promise for Oral Drug Delivery (3 pages)	
116	PURDUE NEWS (September 12, 1997) New Oral Insulin Delivery System Shows Promise (3 pages)	
117	REDONDO et al. (2000) "Overexpression of clusterin in human breast carcinoma." <i>Am J Pathol</i> ; 157:393-399	
118	REUBSAET et al. (1999) "Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg ⁶ , D-Trp ^{7,9} , MePhe ⁸] substance P{6-11}." <i>J. Pharmaceut. & Biomed Analysis</i> 19(3-4):277-284	
119	RUBIN et al. (1991) "Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI." <i>Nature</i> 353:265-267	
120	SEGREST et al. (1974) "A Molecular Theory of Lipid-Protein Interaction in the Plasma Lipoproteins." <i>FEBS Lett.</i> 38: 247-253	
121	SEGREST et al. (1990) "Amphipathic Helix Motif: Classes and Properties." <i>Proteins: Structure, Function and Genetics</i> 8: 103-117	
122	SEGREST et al. (1991) Erratum <i>Proteins: Structure, Function and Genetics</i> 9:79	
123	SEGREST et al. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166.	
124	SEGREST et al. (1994) "The Amphipathic alpha Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins." <i>Adv. Prot. Chem.</i> 45: 303-369	
125	SEGREST et al. (2000) "Structure and function of apolipoprotein A-I and high-density lipoprotein." <i>Current Opin. Lipidol.</i> 11:105-115	
126	SENIOR (1999) "New options developed for needle-free drug delivery" <i>Lancet</i> Sept. 25, 1999	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/120,508
	Filing Date	April 5, 2002
	First Named Inventor	Alan M. Fogelman
	Group Art Unit	1654
	Examiner Name	Jeffrey E. Russel
	Attorney Docket Number	407T-301100US
	Date Submitted	November 26, 2003




127	SHAH et al. (1998) "Effect of Recombinant Apolipoprotein A-I _{Milano} on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice." <i>Circulation</i> 97:780-785.	
128	SILKENSEN et al. (1999) "Identification of clusterin sequences mediating renal tubular cell interactions." <i>J. Pept Res</i> ; 54: 449-457	
129	SINGH et al. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403.	
130	SPRECHER et al. (1993) "The Low HDL Cholesterol/ High Triglyceride Trait." <i>Arterioscler. Thromb.</i> 13: 495-504	
131	SRINIVAS et al. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57.	
132	Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm .	
133	STEINBERG et al. (1997) "Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer." <i>Clin Cancer Res</i> ;3: 1707-1711	
134	SU AND AMIDON (1995) Investigation into the intestinal metabolism of [D-Ala] peptide T amide: implication for oral drug delivery, <i>Biochim et Biophys.</i> , 1245: 62-68	
135	THE WALL STREET JOURNAL (Jan 13, 2000) "Emisphere technologies develops oral Heparin"	
136	TSAI et al. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biol. Psychiatry</i> , 44: 1081-1089	
137	TSAO et al. (2001) "Hibernation-induction Peptide and Cell Death: [D-Ala ² , D-Leu ⁵]enkephalin Blocks Bax-related Apoptotic Processes" <i>European Journal of Pharmacology</i> 428:149-151.	
138	TSIMIKAS et al. (2001) "Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk." <i>Circulation</i> 103:1930-1932	
139	VAN LENTEN et al. (2001) "High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection." <i>Circulation</i> 103:2283-2288.	
140	VAN LENTEN et al. (2001) "Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6." <i>J Biol Chem</i> ;276: 1923-1929	
141	VENKATACHALAPATHI et al. (1993) "Effect of End Group Blockage on the Properties of a Class A Amphipathic Helical Peptide." <i>Proteins:Structure, Function, and Genetics</i> 15:349-359	
142	WEHRLI et al. (2001) "Inhibition of post-ischemic brain injury by clusterin overexpression." <i>Nature Medicine</i> ; 7: 977-978	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL


(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
	Application Number	10/120,508		
	Filing Date	April 5, 2002		
	First Named Inventor	Alan M. Fogelman		
	Group Art Unit	1654		
	Examiner Name	Jeffrey E. Russel		
	Attorney Docket Number	407T-301100US		
Date Submitted	November 26, 2003			

143	WELLMANN <i>et al.</i> (2000) "Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas." <i>Blood</i> ; 96: 398-404	
144	WILSON <i>et al.</i> (1988) "High Density Lipoprotein Cholesterol and mortality: The Framingham Heart Study." <i>Arteriosclerosis</i> 8: 737-741	
145	WONG <i>et al.</i> (2000) "Clusterin protein diversity in the primate eye." <i>Mol. Vision</i> ; 6: 184-191	
146	XU <i>et al.</i> (2000) "Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle" <i>J Biol Chem</i> ; 275: 31770-31777	
147	YANCEY <i>et al.</i> (1995) "Efflux of Cellular Cholesterol and Phospholipid to Lipid-free Apolipoproteins and Class A Amphipathic Peptides." <i>Biochemistry</i> , 34: 7955-7965	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/520,207

Filing Date

April 1, 2003

First Named Inventor

Alan M. Fogelman

Group Art Unit

1654

Examiner Name

Jeffrey E. Russel

Attorney Docket Number

407T-301110US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
- ☐ Amendment / Response
☐ After Final
☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

1449 Copies from Parent
1449 New
4 Cited References
receipt acknowledgment
postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Tom Hunter, Reg. No. 38,498,

Quine Intellectual Property Law Group P.C.

Signature

Date

October 10, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date: October 10, 2005

Typed or printed name

Chianti Appling

Signature

Date

10/10/05